JNJY! ファイナンス2026/8/14 更新

ジョンソン・エンド・ジョンソン

総合スコア
55/100

PR

株式投資の学校

スコアバランス

財務57
ニュース55
掲示板50

財務分析

Wide economic moat spanning patent-protected pharma (Imbruvica, Darzalex, Stelara), medical devices, and iconic consumer health brands with pricing power
Consistently strong and predictable free cash flow generation, supporting sustainable dividends and share repurchases even in macro stress
Defensive demand profile, investment-grade balance sheet metrics, and a 2.05% yield with a payout ratio comfortably below 50% of earnings
!PEG ratio of 4.57x signals rich valuation relative to its historically low-single-digit earnings growth, creating compression risk if near-term results miss
!Tangible book value is negative; P/B of 7.4x is entirely supported by goodwill and intangibles, limiting downside protection from asset-based metrics
!Net debt increased sharply to $28.2B in 2025 from $12.5B in 2024, elevating leverage concerns and reducing financial flexibility in a higher-rate environment

ニュース分析

Transaction volume is too small to signal strategic shift
Likely a routine diversification or 10b5-1 plan execution
!Potential for short-term retail algo overreaction if disclosed without context
!Lack of clarity on insider identity and intent introduces minor uncertainty

掲示板分析

Neutral scoring applied per data‑availability rubric
!Absence of JNJ board data limits sentiment analysis
!Provided news covers macro themes with no JNJ relevance

💡 AI総合分析コメント

総合スコア: 55/100 【財務・株価分析】JNJ trades at a rich PEG of 4.57x relative to its modest mid-single-digit earnings growth trajectory, indicating the market is pricing in defensive stability rather than a bargain. Its diversified moat, robust free cash flow (~$19.3B in 2025), and safe 2.0%+ dividend with >50-year growth history provide a downside floor, but the P/B of 7.4x (driven by intangibles/goodwill) and rising net debt to $28.2B cap upside potential. Without a catalytic pipeline inflection or structural initiative, re-rating likelihood is limited, making the risk/reward asymmetrical to the downside if growth disappoints. 【ニュース分析】The reported insider sale of ~$32M by a JNJ director is immaterial relative to the firm's $450B market cap and ~1.3B share float. No indication of a 10b5-1 plan or executive-level involvement, and the volume represents <0.01% of outstanding. Such transactions are typically routine and already priced in, with no fundamental catalyst embedded; expect minimal price impact and market dismissal as routine liquidity management. 【掲示板分析】The query provides no Johnson & Johnson–specific board sentiment, only unrelated macro news (tariff impacts, yen intervention, AI advancements, climate forecasts). Per the rubric, missing information defaults to a neutral score of 50. Without detectable fear or greed signals, no overheat or panic can be assessed, and a contrarian opportunity cannot be confirmed. JNJ is typically viewed as a defensive, dividend–focused staple, which often attracts steady, long–term holders rather than speculative frenzy.

📰ジョンソン・エンド・ジョンソン の最新ニュース

📚 お役立ちコラム

投資で利益が出たら、確定申告の準備を忘れずに!初心者向けの解説記事も用意しています。